- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01858753
Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
A Phase II, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
This Phase II, double-blind, randomized, placebo-controlled pilot study is designed to determine whether injection of autologous fibroblasts can increase the mobility (decrease the restriction) of burn scars. The study will assess the effects of azficel-T (autologous fibroblasts) in subjects who have a unilateral burn scar that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:
- An axillary scar causing 20-60% restriction of shoulder adduction
- An anterior elbow scar causing 20-60% restriction of elbow extension
- A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension
Subjects will each receive 2 injections of azficel-T or placebo administered 14 days (± 7 days) apart (depending on cell availability) and will be followed for efficacy (including range of motion measurements, scar pain and ability to perform activities) to Visit 7 and for safety to Visit 9 at 1 year.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Univ of California David Medical Center
-
San Diego, California, United States, 92103
- Univ of California San Diego
-
-
Florida
-
Miami, Florida, United States, 33136
- Division of Burns and Trauma, Jackson Memorial Hospital
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Richard M. Fairbanks Burn Center
-
-
New York
-
Garden City, New York, United States, 11530
- Long Island Plastic Surgical Group
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Valley Health Network
-
Pittsburgh, Pennsylvania, United States, 15213
- Center for Innovation in Restorative Medicine
-
-
Washington
-
Seattle, Washington, United States, 98104
- Univ of Washington, Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is at least 18 years of age
Subject has a unilateral burn scar of a jointed area (i.e., finger, elbow, shoulder) that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:
- An axillary scar causing 20-60% restriction of shoulder abduction
- An anterior elbow scar causing 20-60% restriction of elbow extension
- A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension
- Subject's burn scar to be treated is <100 sq cm in size
- Injury occurred ≤ 36 months prior to screening
- By the Investigator's assessment, physical therapy will not provide significant continuous improvement to the range of motion of the subject's joint
- Subject agrees to maintain any current physical therapy regimen for the duration of the study
- Subject must be able to provide written informed consent and comply with the study requirements
- Females of childbearing potential must have a negative urine pregnancy test at the screening visit and prior to the first treatment, and must agree to use a reliable means of birth control for the duration of the study
- Subject has healthy, non-scarred post auricular skin area suitable for biopsy
- Subject must have a normal complete blood count (CBC) and chemistry panel within 90 days prior to enrollment
Exclusion Criteria:
- Restrictive burn scars that are primarily classified as keloid scars
- Subjects for whom a post auricular biopsy cannot be collected for azficel-T production
- Sunburn or sun damage in the area that will be used for biopsy
- Plans to initiate any other new scar therapy during the study period
- Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study
- History of active autoimmune disease or organ transplantation
- Diagnosis of cancer, including basal cell carcinoma, unless successfully treated or in remission for a minimum of 6 months
- Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, epidermolysis bullosa, ataxia-telangiectasia, Ehlers Danlos syndrome, etc.
- Active systemic infection
- Requires chronic antibiotic or steroidal therapy
- Any conditions that are considered by the Investigator to be contraindications to biopsy or injection
- Pregnant or lactating women, or women trying to become pregnant during the study
- Subject has any disorder that may prevent compliance, such as history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the Investigator's opinion, interfere with the study
- Presence of other disease or condition that would result in impairment of the range of motion of the extremity, e.g., rheumatoid arthritis or stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous fibroblasts
Autologous fibroblasts grown in culture from skin biopsy taken from patient.
The cells will be injected into the scars to be treated.
|
Other Names:
|
Placebo Comparator: Sterile saline
Sterile saline will be injected into the scar to be evaluated.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change From Baseline (CFB) of Range of Motion (ROM) of the Affected Joint
Time Frame: Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Time Frame: Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Time Frame: Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Time Frame: Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
|
Percentage CFB of ROM of the Affected Joint
Time Frame: Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)
|
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
|
Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel D Lozano, MD, Lehigh Valley Health Network
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FI-B-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restrictive Burn Scars
-
Castle Creek Biosciences, LLC.WithdrawnRestrictive Burn Scars of Joint AreaUnited States
-
Bispebjerg HospitalCompleted
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Catalysis SLCompleted
-
Massachusetts General HospitalShriners Hospitals for ChildrenUnknownBurn ScarsUnited States
-
Massachusetts General HospitalUnited States Department of Defense; Shriners Hospitals for ChildrenCompleted
-
Association of Dutch Burn CentresCompletedBurns | ScarsNetherlands
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
Stanford UniversityCompletedAvoidant / Restrictive Food Intake Disorder
-
Massachusetts General HospitalAmerican Psychological Foundation; The Hilda & Preston Davis FoundationCompletedAvoidant/Restrictive Food Intake Disorder (ARFID)United States
Clinical Trials on Autologous fibroblasts
-
King's College LondonUniversity College, LondonCompletedRecessive Dystrophic Epidermolysis BullosaUnited Kingdom
-
Federal University of São PauloUnknown
-
Johns Hopkins UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsRecruiting
-
Johns Hopkins UniversityRecruitingAmputation | Skin Wound | Stem CellUnited States
-
Castle Creek Biosciences, LLC.WithdrawnRestrictive Burn Scars of Joint AreaUnited States
-
Castle Creek Biosciences, LLC.CompletedInterdental Papillary InsufficiencyUnited States
-
Castle Creek Biosciences, LLC.CompletedFacial Wrinkles and CreasesUnited States
-
Tego Science, Inc.CompletedTear Trough Eyelid DeformityKorea, Republic of
-
Castle Creek Biosciences, LLC.CompletedAcne Scarring of the FaceUnited States
-
Castle Creek Biosciences, LLC.CompletedBilateral Nasolabial Fold WrinklesUnited States